Recently, global public health has been regarded as an important catalyst of sustainable human development. However, organising a united movement toward the visions of global health is challenging, because LDCs do not have the needed resources. The global emphasis on pharmaceutical regulations and, specifically, on drugs and intellectual property rights (ITR) has been led by deliberations over access to medications in LDCs and the insufficiency of financial support for research and development to deal with ignored and tropical illnesses (Koivusalo 2010). These apprehensions were demonstrated in the agreements prior to the Doha Declaration of WTO on public health (Koivusalo 2010, 395): the development of global programmes, such as the Global Fund to Fight AIDS, Tuberculosis, and Malaria, tackling access to medications for these three illnesses. and the effort of the Commission on Intellectual Property Rights, Innovation, and Public Health of the World Health Organization (WHO).
Nevertheless, although the granting of further financial support for addressing malaria, tuberculosis, and HIV/AIDS and the venture in R&D in mistreated illnesses are definitely imperative, such financial assistances alone are not enough to deal with global health issues. Insufficient research and development and access to medications are normally regarded as issues that exist only in relation to particular illnesses and only in the most impoverished LDCs, and which can be mitigated through an enhanced provision of assistance without additional alterations to industrial regulations, commerce, and innovation worldwide (Sampat 2010). However, this strategy is becoming weak. As mentioned by Koivusalo (2010),